Actinium Pharmaceuticals, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 100 PARK AVE., 23RD FLOOR, NEW YORK, NY, 10017
Mailing Address 100 PARK AVE., 23RD FLOOR, NEW YORK, NY, 10017
Phone (646) 677-3870
Fiscal Year End 1231
EIN 880378336
Financial Overview
FY2025
$44.14M
Total Liabilities
$36.38M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 30, 2026 | View on SEC |
| 8-K/A Current report amendment | March 26, 2026 | View on SEC |
| 8-K Current report of material events | February 13, 2026 | View on SEC |
| 8-K Current report of material events | November 26, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 14, 2025 | View on SEC |
| DEF 14A Definitive proxy statement | November 5, 2025 | View on SEC |
| 4 Insider stock transaction report | August 20, 2025 | View on SEC |
| 10-Q Quarterly financial report | August 8, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | July 29, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | July 16, 2025 | View on SEC |
Annual Reports
10-K March 30, 2026
- Lead candidate Iomab-B addresses a significant market gap in bone marrow transplant preparation.
- ATNM-400 shows potential to outperform current cancer treatments by 3–5 times in tumor reduction.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.